FDA Gets Favorable Response on BsUFA III Commitments

The FDA held a virtual public meeting yesterday to discuss proposed recommendations for the reauthorization of the Biosimilar User Fee Act (BsUFA), the agency’s agreement with regulated industry on reauthorizing user fees for fiscal years 2023 through 2027, and the reception was positive.
Source: Drug Industry Daily